KROS - Keros to extend phase 2 treatment duration of myelodysplastic syndromes candidate

tonaquatic/iStock via Getty Images Keros Therapeutics (KROS) says it will extend the phase 2 treatment duration of myelodysplastic syndromes ("MDS") candidate KER-050 from 12 weeks to up to two years to measure duration of response. Preliminary results released today indicated that as of May 14,  12 patients had received at least one dose, nine of whom completed eight weeks of treatment. Patients in the first two cohorts received 0.75 mg/kg or 1.5 mg/kg doses once every four weeks for 12 weeks. Results showed that five patients that completed eight weeks of treatment met at least one endpoint. These were: increase in hemoglobin ? 1.5 g/dL for eight weeks; 50% reduction in transfusion requirements over eight weeks; or transfusion independence for at least eight weeks. No drug-related serious adverse events were reported. The company said the results demonstrate proof-of-concept for KER-050 in very low-, low- to intermediate-risk MDS. Keros shares closed down 1.6% to $52.58

For further details see:

Keros to extend phase 2 treatment duration of myelodysplastic syndromes candidate